Table 1.
Diagnoses, and Female Age within Treatment Groups a
| Treatment Group |
|||||||
|---|---|---|---|---|---|---|---|
| Total cohort (n = 398) |
No cycle- based treatment (n = 86; 21.6%) |
Medications only, no other intervention (n = 17; 4.3%) |
IUI-C (n = 39; 9.8%) |
IUI-FSH (n = 44; 11.1%) |
IVF (n = 188; 47.2%) |
IVF-DE (n = 24; 6.0%) |
|
| Diagnoses, % (n) b | |||||||
| Male factor | 37.7 (150) | 20.7 (31) c | 1.3 (2) | 8.0 (12) | 5.3 (8) | 61.3 (93) | 3.3 (5) |
| Female, tubal | 14.6 (57) | 21.1 (12) | 3.5 (2) | 3.5 (2) | 3.5 (2) | 59.7 (34) | 8.8 (5) |
| Female, uterine | 12.8 (50) | 28.0 (14) | 4.0 (2) | 8.0 (4) | 14.0 (7) | 42.0 (21) | 4.0 (2) |
| Female, ovarian | 39.0 (152) | 27.0 (41) | 2.6 (4) | 5.3 (8) | 10.5 (16) | 40.8 (63) | 13.8 (21) |
| Female, ovulatory | 28.2 (110) | 15.5 (17) | 8.2 (9) | 15.5 (17) | 20.0 (22) | 40.9 (45) | 0 |
| Unexplained | 9.3 (37) | 21.6 (8) | 0 | 27.0 (10) | 8.1 (3) | 40.5 (15) | 2.7 (1) |
| Age group, % (n) | |||||||
| ≤ 35 years, | 48.0 (191) | 18.4 (35) | 4.7 (9) | 13.7 (26) | 10.5 (20) | 50.0 (95) | 2.6 (5) |
| 36-39 years | 29.3 (116) | 21.6 (25) | 2.6 (3) | 5.2 (6) | 12.1 (14) | 53.5 (62) | 5.2 (6) |
| ≥ 40 years | 22.7 (90) | 28.9 (26) | 5.6 (5) | 7.8 (7) | 11.1 (10) | 32.2 (29) | 14.4 (13) |
|
Treatments prior to study entry, % (n) d |
|||||||
| No prior treatment | 31.9 (120) | 30.0 (36) | 3.3 (4) | 15.8 (19) | 6.7 (8) | 36.7 (44) | 7.5 (9) |
| Medications only | 35.1 (132) | 24.2 (32) | 8.3 (11) | 10.6 (14) | 12.9 (17) | 38.6 (51) | 5.3 (7) |
| IUI-C | 31.7 (119) | 11.8 (14) | 0 | 3.4 (4) | 14.3 (17) | 64.7 (77) | 5.9 (7) |
| IUI-FSH | 17.8 (67) | 13.4 (9) | 0 | 1.5 (1) | 11.9 (8) | 68.7 (46) | 4.5 (3) |
a
Subjects were placed into treatment groups according to the highest intensity of treatment they received during the study period.
b
Diagnosis categories are not mutually exclusive. Definitions of diagnostic groups are as follows:
- tubal (e.g., damaged, blocked, removed Fallopian tubes; ectopic pregnancy);
- uterine (e.g., intrauterine adhesions, fibroids);
- ovarian (e.g., diminished ovarian reserve, “advanced maternal age,” elevated FSH);
- ovulatory (e.g., amenorrhea, luteal phase defect, polycystic ovarian disease).
c
Reflects percent (n) within each treatment (or age) group. Row percentages of treatment groups should sum to 100%.
d
Treatments prior to study entry are not mutually exclusive, except for “no prior treatment.”